HanchorBio Brings Clinical Anchor-to-Platform Strategy to BIO Asia–Taiwan 2026
Oral presentation and Booth L221 to connect HCB101 clinical development, FBDB™ platform expansion, and global collaboration opportunities
[Taipei, Shanghai, San Francisco | July 13, 2026] – HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-related diseases, today announced that it will present its clinical development and platform strategy at BIO Asia–Taiwan 2026, taking place July 16–19, 2026, in Taipei, Taiwan.
HanchorBio comes to BIO Asia–Taiwan following a period of progress across clinical development, regulatory strategy, scientific collaboration, global partnering, and capital-market engagement. Together, these activities reflect a clear development model: establish a strong clinical anchor, learn from the biology emerging around it, expand through rational combinations, and translate those learnings into the next generation of multi-functional immunotherapies.
Immunity was never one-dimensional. Neither are we.
That belief shapes how HanchorBio develops medicines: start with evidence, follow the biology, and build what comes next.
Recent Momentum Across Clinical Development, Regulatory Strategy, and Collaboration
HCB101, HanchorBio’s engineered SIRPα-IgG4 Fc fusion protein, serves as the Company’s lead clinical anchor and is being developed as a potential myeloid-enhancing immune backbone for rational combination therapy.
Recent clinical data presented at the JCA–AACR Special Joint Conference in Kyoto provided additional evidence in gastric/gastroesophageal junction cancer and head and neck squamous cell carcinoma. Second-line gastric/GEJ cancer remains the lead development setting for HCB101, while emerging clinical and translational learnings are guiding the evaluation of selected expansion opportunities in tumor settings where myeloid biology, immune exclusion, and treatment resistance may play important roles.
The Company’s recent FDA Type C interaction further clarified the next stage of HCB101 development in second-line gastric/GEJ cancer, supporting continued dose and schedule optimization in combination with ramucirumab and paclitaxel, followed by a planned randomized Phase 2b lead-in strategy toward confirmatory development.
In parallel, HanchorBio is extending its strategy through biology-driven combinations. The Company’s recently announced strategic MOU with InxMed to explore complementary approaches to overcoming tumor microenvironment barriers in difficult-to-treat solid tumors.
Bringing the Strategy Together at BIO Asia–Taiwan
At BIO Asia–Taiwan, HanchorBio will bring these elements together through both scientific presentation and direct engagement with potential partners, collaborators, and investors.
On July 17, 2026, Wenwu Zhai, Ph.D., Chief Scientific Officer of HanchorBio, will deliver an oral presentation titled “Redefining Immuno-Oncology Through Multi-Functional Fc-Based Designer Biologics (FBDB) Platform.”
The presentation will describe HanchorBio’s approach to designing multi-functional biologics that bring complementary immune mechanisms together within a single molecular architecture, as well as the relationship between the Company’s clinical programs and its broader FBDB™ platform strategy.
Throughout the conference, HanchorBio will also exhibit at Booth L221, where the Company will showcase the HCB101 development strategy, its broader clinical pipeline, next-generation FBDB™ programs, and opportunities for licensing, combination development, and co-development.
Extending Global Engagement from the United States to Asia
The discussions HanchorBio brings to BIO Asia–Taiwan did not begin in Taipei.
In recent weeks, the Company has been engaging different parts of the global biotechnology ecosystem around a central question: how can a clinically informed myeloid strategy become a broader immunotherapy platform?
At BIO International 2026, HanchorBio’s business development team engaged with global biotechnology, pharmaceutical, and strategic partners. In parallel, Company leadership met with institutional investors and capital-market participants in New York and Boston to discuss HanchorBio’s clinical anchor-to-platform strategy and global development plans.
These conversations have also reinforced the importance of distinguishing HanchorBio’s strategy from first-generation CD47 drug development. The Company is building from a differentiated SIRPα-based clinical anchor, applying disciplined clinical and regulatory development, and using emerging evidence to guide rational combinations and next-generation multi-axis biologics.
BIO Asia–Taiwan now brings these threads together: new clinical evidence, a clearer regulatory path, biology-driven collaboration, global partnering, and U.S. capital-market engagement—at home, for a company building globally.
From Clinical Anchor to Platform Expansion
HanchorBio’s strategy begins with HCB101, but it does not end there.
Clinical and translational learnings from HCB101 are informing the Company’s broader FBDB™ platform strategy. Programs including HCB301 and HCB303 extend the approach toward multi-axis immunotherapy, while additional programs explore the relevance of myeloid biology beyond oncology.
Clinical anchor → rational expansion → platform optionality.
“BIO Asia–Taiwan comes at the right moment for HanchorBio,” said Scott Liu, Ph.D., Founder and Chairman of HanchorBio. “Recent progress across clinical development, regulatory planning, combination strategy, and global engagement has brought greater clarity to how we build from here. HCB101 is our clinical anchor. FBDB™ is our platform engine. Collaboration is how we expand the opportunity.”
“With our roots in Taiwan and building globally. BIO Asia–Taiwan gives us an important home-market platform to connect the clinical evidence we are generating, the biology we are learning from, and the partnerships that can help us move faster. Immunity was never one-dimensional. We believe the next generation of immunotherapy should be designed with that reality in mind.”
About HanchorBio
HanchorBio (TWSE: 7827) is a global clinical-stage biotechnology company developing next-generation immunotherapies based on a fundamental belief: immunity is not one-dimensional, and the medicines designed to harness it should not be either.
Rooted in Taiwan with operations in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio is advancing a pipeline of immunotherapies for oncology and immune-mediated diseases. The Company’s proprietary Fc-Based Designer Biologics (FBDB™) platform enables the design of multi-functional biologics that bring complementary immune mechanisms together within a single molecular architecture.
HanchorBio’s clinical pipeline is anchored by HCB101, an engineered SIRPα-IgG4 Fc fusion protein designed to restore macrophage-mediated antitumor activity and enable rational combination strategies. Clinical and translational learnings from HCB101 inform the Company’s broader platform expansion, including multi-axis immunotherapies and programs beyond oncology.
Listed on the Taiwan Stock Exchange Innovation Board (TWSE: 7827), HanchorBio is advancing its clinical development, regulatory strategy, and global partnerships from a foundation built in Taiwan and designed for global development.
Forward-Looking Statements
This press release contains forward-looking statements regarding HanchorBio’s clinical development programs, product candidates, regulatory strategy, and future plans. Actual results may differ materially from those expressed or implied due to various risks and uncertainties, including clinical development outcomes, regulatory interactions and decisions, protocol development, execution of collaboration, and market conditions. HanchorBio undertakes no obligation to update forward-looking statements except as required by applicable law.
漢康-KY攜「臨床定錨到平台拓展」策略亮相BIO Asia–Taiwan 2026
口頭報告與L221展位將聚焦HCB101臨床開發、FBDB™平台拓展及全球合作機會
【台北、上海、舊金山｜2026年7月13日】 — 漢康生技股份有限公司（HanchorBio, Inc.，TWSE：7827；以下簡稱「漢康-KY」），一家專注於腫瘤與免疫相關疾病之新一代免疫療法開發的全球臨床階段生技公司，今日宣布將參與2026亞洲生技大會（BIO Asia–Taiwan 2026）。本屆大會將於2026年7月16日至19日在台北舉行。
漢康-KY此次參與BIO Asia–Taiwan，正值公司在臨床開發、法規策略、科學合作、全球商務拓展及資本市場溝通等面向持續推進的重要階段。這些進展並非單一事件，而是共同指向一個清楚的發展邏輯：以HCB101建立臨床定錨，從臨床與轉譯科學中學習生物學訊號，再依據機制合理拓展聯合療法與平台化開發機會。
免疫，從來不只一面。我們，也一樣。
這也是漢康-KY發展新藥的核心信念：從臨床證據出發，順著生物學前進，打造下一代多功能免疫療法。
臨床開發、法規策略與合作布局持續推進
HCB101為漢康-KY自主開發的工程化SIRPα-IgG4 Fc融合蛋白，也是公司目前最重要的臨床定錨資產。HCB101以CD47–SIRPα軸為核心，定位為具潛力的髓系免疫增強型治療骨幹，並可支持後續合理聯合療法開發。
近期，漢康-KY於日本京都舉行的JCA–AACR特別聯合會議中發表HCB101於胃癌／胃食道交界癌及頭頸部鱗狀細胞癌的臨床資料，為後續開發策略提供更多臨床與轉譯依據。二線胃癌／胃食道交界癌仍為HCB101目前的主要臨床開發方向；同時，相關臨床觀察也正協助公司評估在髓系生物學、免疫排斥與治療抗性較明顯之腫瘤類型中的拓展機會。
公司近期與美國FDA進行的Type C溝通，也進一步釐清HCB101於二線胃癌／胃食道交界癌的下一階段開發路徑。漢康-KY將持續推進HCB101與ramucirumab及paclitaxel聯合使用的劑量與給藥時程優化，並規劃以隨機化Phase 2b lead-in設計銜接後續確認性臨床開發。
此外，漢康-KY也持續透過生物學驅動的聯合策略拓展HCB101的開發潛力。公司近期宣布與應世生物（InxMed）簽署策略合作備忘錄，雙方將探索互補性機制，以克服難治實體瘤中的腫瘤微環境屏障。
在BIO Asia–Taiwan整合呈現公司策略
於BIO Asia–Taiwan期間，漢康-KY將透過科學報告與展位交流，完整呈現其臨床定錨到平台拓展的發展策略。
2026年7月17日，漢康-KY首席科學長翟文武博士將進行口頭報告，題目為：
「Redefining Immuno-Oncology Through Multi-Functional Fc-Based Designer Biologics (FBDB) Platform」
本次報告將說明漢康-KY如何透過FBDB™平台設計多功能生物藥，將互補性的免疫機制整合於單一分子架構中，並進一步闡述公司臨床資產與平台拓展策略之間的關聯。
大會期間，漢康-KY也將於L221展位展示HCB101臨床開發策略、整體臨床管線、新一代FBDB™平台項目，以及產品授權、聯合療法開發與共同開發等合作機會。
從美國到亞洲，延續全球對話
漢康-KY此次帶到BIO Asia–Taiwan的討論，並不是從台北才開始。
近幾週，公司已與全球生技生態系中的不同參與者持續交流，圍繞一個核心問題展開：如何將臨床證據所支持的髓系免疫策略，延伸為更廣泛的免疫療法平台？
在BIO International 2026期間，漢康-KY商務拓展團隊透過BIO Partnering™與全球生技、製藥及策略合作夥伴進行交流。同時，公司高階管理團隊亦於紐約及波士頓與機構投資人及資本市場夥伴會面，討論漢康-KY「臨床定錨到平台拓展」策略及全球發展規劃。
這些交流也進一步凸顯漢康-KY策略與第一代CD47藥物開發的差異。漢康-KY並非重複既有CD47開發模式，而是以差異化SIRPα臨床資產為起點，透過嚴謹的臨床與法規執行，並依據持續累積的證據推進合理聯合療法與下一代多軸免疫療法。
BIO Asia–Taiwan將使這些線索在亞洲進一步匯聚：新的臨床證據、更清楚的法規路徑、生物學驅動的合作、全球商務拓展，以及美國資本市場交流——在台灣這個重要據點，呈現一家根植台灣、布局全球的生技公司如何持續前進。
從臨床定錨到平台拓展
漢康-KY的策略始於HCB101，但不止於HCB101。
HCB101所累積的臨床與轉譯科學經驗，正持續回饋並推動公司更廣泛的FBDB™平台策略。包括HCB301與HCB303在內的後續項目，進一步將平台拓展至多軸免疫療法；其他項目則探索髓系生物學在腫瘤以外疾病領域中的潛在應用。
臨床定錨 → 合理拓展 → 平台選擇性。
漢康-KY創辦人暨董事長劉世高博士表示：「BIO Asia–Taiwan對漢康-KY而言正逢其時。近期在臨床開發、法規規劃、聯合療法策略與全球交流上的進展，讓我們更清楚看見公司下一階段應如何建構。HCB101是我們的臨床定錨，FBDB™是我們的平台引擎，而合作，則是拓展機會的重要方式。」
劉世高博士進一步表示：「漢康-KY根植台灣，並以全球為舞台持續發展。BIO Asia–Taiwan提供了一個重要平台，讓我們能夠把正在累積的臨床證據、正在學習的生物學，以及能夠加速前進的合作夥伴連結在一起。免疫，從來不只一面。我們相信，下一代免疫療法也應該依據這個現實來設計。」
亞洲生技大展 BioAsia 大會資訊
時間｜7/16（四）-19（日）10:00–18:00 (最後一日至17:00)
地點｜台北南港展覽館一館 4F
漢康生技攤位號｜L221展位
公司展望說明會
時間｜7/17（五）15:45–16:00
地點｜台北南港展覽館一館 4F，N913 展位
主講人｜漢康生技 研發長 翟文武博士
關於漢康-KY：
英屬開曼群島商漢康生技股份有限公司（以下簡稱“漢康-KY”，股票代碼：7827）成立於2020年，由具豐富國際藥物開發與運營經驗的劉世高博士創辦。公司專注於腫瘤免疫藥物研發，透過自主建立的核心「FBDB多功能融合蛋白技術平台」開發出8+種創新蛋白生物藥，具有廣譜抗癌潛力，可抑制多種實體瘤及血液腫瘤，並持續取得多項專利。其中HCB101與HCB301已進入臨床試驗階段，而HCB101在2025年6月更完成首項國際授權，總授權金達2.02億美元。漢康-KY的策略是以多功能生物藥克服現行採取免疫療法與化療並行的高失敗率，同時藉由啟動先天性免疫和適應性免疫體系以摧毀腫瘤，致力提供高效且可負擔的新一代腫瘤免疫治療方案，解決未滿足的醫療需求。
聲明：
本新聞稿及同時發佈之相關資訊內含有預測性敘述；其內容乃根據既有之風險及可能的不確定性進行判斷及預測，包括：市場因素與其他非漢康-KY（以下簡稱本公司）所能掌控之原因。這些預測性敘述是基於現況的預測和評估，除非基於法律的要求，本公司不負日後更新之責。